A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

BACKGROUND: IgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies. Bruton’s tyrosine kinase (BTK) is an essential enzyme for IgE-mediated signaling pathways and is an ideal pharmacologic target to prevent aller...

Descripción completa

Detalles Bibliográficos
Autores principales: Suresh, Ragha V., Dunnam, Collin, Vaidya, Dhananjay, Wood, Robert A., Bochner, Bruce S., MacGlashan, Donald W., Dispenza, Melanie C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425211/
https://www.ncbi.nlm.nih.gov/pubmed/37384412
http://dx.doi.org/10.1172/JCI172335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425211/
https://www.ncbi.nlm.nih.gov/pubmed/37384412
http://dx.doi.org/10.1172/JCI172335

Ejemplares similares